{"product_id":"akba-vrio-analysis","title":"Akebia Therapeutics, Inc. (AKBA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Akebia Therapeutics, Inc. (AKBA) truly built to last? This concise VRIO analysis cuts straight to the chase, evaluating whether its core assets possess the necessary Value, Rarity, Inimitability, and Organization to secure a sustainable competitive edge. Dive in now to see the distilled summary of its true market power and strategic implications.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Vafseo (Vadadustat) U.S. Commercialization Platform for Dialysis CKD Anemia\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at the early commercial success of Vafseo in the dialysis setting, and frankly, the initial numbers show a solid start for a new drug launch. My take, based on the Q3 2025 data, is that Akebia Therapeutics has built a strong, albeit temporary, moat around this product right now.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math: Vafseo net product revenue for the first three quarters of fiscal 2025 totaled \u003cstrong\u003e$39.6 million\u003c\/strong\u003e ($12.0M in Q1, $13.3M in Q2, and $14.3M in Q3). The company ended Q3 with cash and equivalents of \u003cstrong\u003e$166.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003eVafseo (Vadadustat) U.S. Commercialization Platform for Dialysis CKD Anemia\u003c\/h\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Drives significant revenue growth, with $39.6 million in nine-month 2025 revenue and strong initial prescriber adoption.\u003c\/strong\u003e The product is clearly generating top-line results, hitting that \u003cstrong\u003e$39.6 million\u003c\/strong\u003e mark through September 30, 2025. Adoption is strong where access is established; for instance, over \u003cstrong\u003e85%\u003c\/strong\u003e of U.S. Renal Care physicians have already written a prescription.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; while other treatments exist, the specific HIF-PH inhibitor class and recent U.S. launch create a current niche.\u003c\/strong\u003e Vafseo is the first in its class (hypoxia-inducible factor, or HIF-PH inhibitor) to gain traction in the U.S. market following its January 2025 shipment start. This first-mover advantage in a new mechanism of action gives it a temporary edge over older, established therapies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult; imitation requires FDA approval, establishing reimbursement, and building the specialized sales force that secured access for 275,000 patients by year-end.\u003c\/strong\u003e The barrier isn't just the science; it's the operational execution. Akebia secured commercial supply agreements covering nearly \u003cstrong\u003e100%\u003c\/strong\u003e of U.S. dialysis patients. Replicating that level of provider integration, especially securing Transitional Drug Add-on Payment Adjustment (TDAPA) reimbursement, is a massive undertaking that takes time and capital.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High; the company is organized to drive Vafseo toward standard of care, expecting to quadruple prescribing access by year-end 2025.\u003c\/strong\u003e Management is focused on execution, moving from an initial access base of about \u003cstrong\u003e40,000\u003c\/strong\u003e patients at the end of Q2 to a target of \u003cstrong\u003e275,000\u003c\/strong\u003e patients by year-end. This goal represents roughly four times the access achieved by the end of Q3, showing clear internal alignment on market penetration.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; initial lead is strong, but success attracts competition in the HIF-PH space.\u003c\/strong\u003e The current advantage is real because of the early access and physician interest, but the HIF-PH space is where other players will focus their R\u0026amp;D. Competitors will be gunning for this mechanism, so this lead won't last forever.\u003c\/p\u003e\n\n\u003cp\u003eHere is a quick scoring breakdown of the VRIO dimensions:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n    \u003cth\u003eAssessment\u003c\/th\u003e\n    \u003cth\u003eScore (1-4)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes, drives revenue (\u003cstrong\u003e$39.6M\u003c\/strong\u003e YTD)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes, first-in-class mechanism in U.S. market\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitability\u003c\/td\u003e\n    \u003ctd\u003eDifficult due to operational\/reimbursement hurdles\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eYes, focused on achieving \u003cstrong\u003e275,000\u003c\/strong\u003e patient access by year-end\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe immediate action is to monitor the DaVita pilot completion in November, as that should unlock the final leg of the year-end access goal. If they hit \u003cstrong\u003e275,000\u003c\/strong\u003e patients, the next focus shifts to prescription conversion rates.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eCommercial: Finalize DaVita protocol integration by November 30.\u003c\/li\u003e\n  \u003cli\u003eFinance: Model Q4 revenue based on \u003cstrong\u003e275,000\u003c\/strong\u003e access points.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Auryxia (Ferric Citrate) Established Revenue Base\n\u003c\/h2\u003e\n\u003cp\u003e\nAuryxia (ferric citrate) net product revenues for the first three quarters of 2025 totaled \u003cstrong\u003e$133.5 million\u003c\/strong\u003e, calculated from the sum of Q1 2025 ($43.8 million), Q2 2025 ($47.2 million), and Q3 2025 ($42.5 million) net product revenues.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eVRIO Assessment:\u003c\/strong\u003e\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a stable, significant revenue foundation.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Product Revenue in Q1 2025: \u003cstrong\u003e$43.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Product Revenue in Q2 2025: \u003cstrong\u003e$47.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Product Revenue in Q3 2025: \u003cstrong\u003e$42.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Net Product Revenue for the first nine months of 2025: \u003cstrong\u003e$133.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Low.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLoss of Exclusivity (LoE) occurred on \u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrior to LoE, Q4 2024 revenue was \u003cstrong\u003e$44.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe market for iron replacement therapies is established.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCompetitors can offer generics or similar products.\u003c\/li\u003e\n\u003cli\u003eAkebia maintains \u003cstrong\u003eone authorized generic\u003c\/strong\u003e for Auryxia sold by its distributor.\u003c\/li\u003e\n\u003cli\u003eMultiple patent litigation settlements were reached with generic filers, including licenses beginning on \u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExisting infrastructure manages Auryxia sales alongside the Vafseo launch, which began in January 2025.\u003c\/li\u003e\n\u003cli\u003eContracts cover nearly \u003cstrong\u003e100% of dialysis lives\u003c\/strong\u003e for Vafseo, indicating established organizational reach in the relevant patient segment.\u003c\/li\u003e\n\u003cli\u003eThe company reported net income of \u003cstrong\u003e$0.2 million\u003c\/strong\u003e in Q2 2025, partially due to improved margin profile after Auryxia amortization ended.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nCompetitive dynamics and revenue performance are summarized below:\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryxia Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryxia Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$47.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuryxia Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Auryxia Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$133.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst Nine Months of 2025 (Sum of Q1-Q3)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLoss of Exclusivity Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 20, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAuthorized Generic Entry\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVafseo Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVafseo Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVafseo Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$57.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$62.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nCompetitive Landscape Context:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAuryxia competes with other non-calcium-containing binders such as sevelamer, lanthanum, and sucroferric oxyhydroxide.\u003c\/li\u003e\n\u003cli\u003eVafseo (vadadustat) began U.S. market launch in January 2025.\u003c\/li\u003e\n\u003cli\u003eVafseo net product revenues reached \u003cstrong\u003e$14.3 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eAs of Q3 2025, the total number of Vafseo prescribers was approximately \u003cstrong\u003e725\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nFinancial Position Context:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of September 30, 2025, were approximately \u003cstrong\u003e$166.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet income for Q2 2025 was \u003cstrong\u003e$0.2 million\u003c\/strong\u003e, compared to a net loss of $8.6 million in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eAkebia estimates it has at least \u003cstrong\u003e12 months\u003c\/strong\u003e of Vafseo inventory on hand in the U.S. free of potential incremental tariff payments as of Q1 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Integrated Renal Disease R\u0026amp;D and Commercialization Infrastructure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntegrated Renal Disease R\u0026amp;D and Commercialization Infrastructure\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for end-to-end management of drug lifecycle, from research to market access, as evidenced by the Vafseo launch.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; being fully integrated in the specialized renal space is less common than outsourcing one function.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Costly and time-consuming; building this dual capability over time is hard to copy quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company has successfully launched Vafseo and is now focusing on a Rare Kidney Disease Pipeline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while costly to build, a competitor could acquire a similar integrated entity.\u003c\/p\u003e\n\n\u003cp\u003eThe integrated infrastructure supports both the development of new assets and the commercial execution for existing and new products within the kidney disease space.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eInfrastructure Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment (Recent)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 Research \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Reach (USRC Partnership)\u003c\/td\u003e\n\u003ctd\u003eU.S. Renal Care (USRC) Dialysis Centers\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e500\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Reach (USRC Partnership)\u003c\/td\u003e\n\u003ctd\u003eUSRC Kidney Disease Patients Served\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e36,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct Portfolio Status\u003c\/td\u003e\n\u003ctd\u003eTotal FDA-Approved Products\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Progress (VOICE Study)\u003c\/td\u003e\n\u003ctd\u003eEnrollment Completion Percentage\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e75%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Liquidity\u003c\/td\u003e\n\u003ctd\u003eCash and Cash Equivalents (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$137 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey statistical and financial data points demonstrating the operational scale:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVafseo US Net Product Revenues in Q1 2025: \u003cstrong\u003e$12 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVafseo Net Product Revenues in Q2 2025: \u003cstrong\u003e$13.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAuryxia Net Product Revenues in Q2 2025: \u003cstrong\u003e$47.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Revenues in Q2 2025: \u003cstrong\u003e$62.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eU.S. Chronic Kidney Disease (CKD) Population: Approximately \u003cstrong\u003e35.5 million\u003c\/strong\u003e people.\u003c\/li\u003e\n\u003cli\u003eProjected Global Dialysis Segment Compound Annual Growth Rate (CAGR) through 2032: \u003cstrong\u003e8.4%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected full Transitional Drug Add-on Payment Adjustment (TDAPA) designation for Vafseo: January 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Intellectual Property for HIF-PH Inhibitor Pathway (Vafseo)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eIntellectual Property for HIF-PH Inhibitor Pathway (Vafseo)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 id=\"value\"\u003eValue\u003c\/h3\u003e\n\u003cp\u003eProtects the core mechanism of action for Vafseo, which has shown statistically more favorable composite outcomes versus ESAs in post-hoc analysis.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eVafseo Data Point\u003c\/th\u003e\n\u003cth\u003eComparator\/Context\u003c\/th\u003e\n\u003cth\u003eTimeframe\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eComposite Outcome\u003c\/td\u003e\n\u003ctd\u003eLower risk of death or hospitalization\u003c\/td\u003e\n\u003ctd\u003evs. Darbepoetin alfa (ESA)\u003c\/td\u003e\n\u003ctd\u003ePost-hoc Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorsening of Hypertension\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e14%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003evs. \u003cstrong\u003e17%\u003c\/strong\u003e for Darbepoetin alfa\u003c\/td\u003e\n\u003ctd\u003ePost-hoc Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSerious GI Erosions\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003evs. \u003cstrong\u003e3.3%\u003c\/strong\u003e for Darbepoetin alfa\u003c\/td\u003e\n\u003ctd\u003ePost-hoc Analysis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHepatocellular Injury\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLess than 1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported incidence\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Product Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eVafseo specific revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 id=\"rarity\"\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; the specific IP around vadadustat and its application is proprietary.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUS Drug Patents filed: \u003cstrong\u003e13\u003c\/strong\u003e (in \u003cstrong\u003e2024\u003c\/strong\u003e)\u003c\/li\u003e\n\u003cli\u003eOne solid form patent expiry date: \u003cstrong\u003eNovember 14, 2034\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 id=\"imitability\"\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult; patent protection is a legal barrier, though the science itself is known.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEstimated Generic Launch Date: \u003cstrong\u003eMar 31, 2036\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNCE-1 Date: \u003cstrong\u003eMarch 27, 2028\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eLast Outstanding Exclusivity Expiry: \u003cstrong\u003e2029\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 id=\"organization\"\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; the IP underpins the entire Vafseo commercial strategy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCommercial supply contracts in place covering nearly \u003cstrong\u003e100%\u003c\/strong\u003e of U.S. dialysis patients at launch\u003c\/li\u003e\n\u003cli\u003eFDA Approval Date: \u003cstrong\u003eMarch 27, 2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eVafseo U.S. Launch: \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDecision to not pursue broad label for non-dialysis dependent patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ch3 id=\"competitive-advantage\"\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained (while patents hold); this is the legal moat around the product.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProtection Type\u003c\/th\u003e\n\u003cth\u003eKey Date\/Metric\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Challenge Window Opens\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 27, 2028\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEarliest date for generic challenge filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated Generic Entry\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMar 31, 2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLong-term protection estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Approval Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStart of market exclusivity period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Praliciguat Exclusive Global License\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Offers pipeline diversification beyond the core focus, with potential future upside in rare kidney disease indications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; securing an exclusive global license for a novel sGC stimulator is a unique asset within the current portfolio.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; the exclusivity is contractually protected, and the asset itself is unique, though prior Phase 2 trial results in other indications present a risk factor.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the company is actively pursuing development in Focal Segmental Glomerulosclerosis (FSGS) but has not yet committed significant commercialization resources for this asset.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the value is contingent on future development success, particularly in the ongoing Phase 2 trial for FSGS.\u003c\/p\u003e\n\n\u003cp\u003eThe financial structure of the Exclusive Global License, originally established with Cyclerion Therapeutics in June 2021 and subsequently amended in December 2024, is detailed below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eOriginal Term (2021)\u003c\/th\u003e\n\u003cth\u003eAmended Term (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment to Licensor\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3.0 million\u003c\/strong\u003e (Paid in 2021)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.25 million\u003c\/strong\u003e paid before December 31, 2024, plus \u003cstrong\u003e$0.5 million\u003c\/strong\u003e on or before September 30, 2025 (Total near-term: \u003cstrong\u003e$1.75 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Future Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$585 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$560 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Commercial Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$225 million\u003c\/strong\u003e (including up to \u003cstrong\u003e$15 million\u003c\/strong\u003e in first 18 months)\u003c\/td\u003e\n\u003ctd\u003e(Included in the reduced total milestone figure)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales-Based Royalties (Tiered)\u003c\/td\u003e\n\u003ctd\u003eSingle-digit to high-teen percentages\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eMid-single-digits to twenty percent\u003c\/strong\u003e of net sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Expense Responsibility\u003c\/td\u003e\n\u003ctd\u003eShared\/Not explicitly detailed as transferred\u003c\/td\u003e\n\u003ctd\u003eAkebia assumes responsibility for certain IP expenses after \u003cstrong\u003eQ1 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe development history and current focus for Praliciguat include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitially studied in Phase 2 trials for Diabetic Nephropathy (DN) and Heart Failure with Preserved Ejection Fraction (HFpEF).\u003c\/li\u003e\n\u003cli\u003eThe DN Phase 2 study was expected to enroll approximately \u003cstrong\u003e150 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe HFpEF Phase 2 trial (CAPACITY-HFpEF) was expected to enroll approximately \u003cstrong\u003e184 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePraliciguat is currently in \u003cstrong\u003ePhase I\u003c\/strong\u003e for Focal Segmental Glomerulosclerosis (FSGS).\u003c\/li\u003e\n\u003cli\u003eThe planned Phase 2 clinical trial in FSGS is expected to enroll up to \u003cstrong\u003e60 patients\u003c\/strong\u003e at U.S. sites.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Recent Pipeline Expansion via Acquisition (AKB-097)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eRecent Pipeline Expansion via Acquisition (AKB-097)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Adds a Phase 2 complement inhibitor, AKB-097, diversifying the portfolio beyond the HIF-PH pathway and providing upside. AKB-097 is a humanized anti-C3d Factor H monoclonal antibody fusion protein designed to inhibit complement activation through a tissue-targeted mechanism, potentially addressing limitations of systemic inhibitors like infection risk. The Phase 2 basket study is planned to begin in the \u003cstrong\u003esecond half of 2026\u003c\/strong\u003e, with initial data expected in \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; acquiring a Phase 2 asset is not unique, but the specific asset is. AKB-097 has demonstrated distribution to affected tissues and organs with a durable tissue pharmacokinetic and pharmacodynamic profile in preclinical work, and was well-tolerated in a completed Phase 1 trial in healthy volunteers.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy; competitors can make similar acquisitions, though the price paid sets a precedent. The structure of the deal involves initial and near-term payments, aligning incentives.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the acquisition was executed to enhance the pipeline, showing strategic intent. This move establishes a rare kidney disease pipeline alongside the Praliciguat Phase 2 trial, which is targeting up to \u003cstrong\u003e60 patients\u003c\/strong\u003e in the U.S. for Focal Segmental Glomerulosclerosis (FSGS), a condition affecting approximately \u003cstrong\u003e40,000\u003c\/strong\u003e people in the U.S. The company reported a Q3 2025 Net Income of \u003cstrong\u003e$540,000\u003c\/strong\u003e, a significant improvement from a \u003cstrong\u003e$20 million\u003c\/strong\u003e net loss in Q3 2024, with Q3 2025 Revenue at \u003cstrong\u003e$58.76 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage is in being first to secure this specific asset and advancing it through the planned \u003cstrong\u003e2026\u003c\/strong\u003e Phase 2 enrollment.\u003c\/p\u003e\n\n\u003cp\u003eThe financial terms of the Asset Purchase Agreement (APA) for AKB-097 are detailed below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeal Term Component\u003c\/td\u003e\n\u003ctd\u003eAmount\/Description\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment (Initial)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNear-Term Milestone Payment (6-Month)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNear-Term Milestone Payment (By End of 2026)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Near-Term Payments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Development\/Regulatory Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$592 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Commercial Milestones \u0026amp; Royalties\u003c\/td\u003e\n\u003ctd\u003eTiered royalties on net sales (low single-digit to mid-teen percentages)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe strategic pipeline expansion is further supported by the company's recent financial performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$58.76 million\u003c\/strong\u003e (Exceeded forecast of \u003cstrong\u003e$52.06 million\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Income: \u003cstrong\u003e$540,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 EPS: \u003cstrong\u003e$0\u003c\/strong\u003e (Beat forecasted EPS of \u003cstrong\u003e-$0.04\u003c\/strong\u003e).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Strong Balance Sheet and Cash Runway (as of Q3 2025)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nProvides operational flexibility and security. Cash and cash equivalents as of September 30, 2025, were approximately \u003cstrong\u003e$166.4 million\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Amount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$166.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nModerate; many small biotechs struggle with cash, but Akebia is financed to achieve profitability based on its current plan. Akebia believes its existing cash resources and expected revenues are sufficient to fund current operating plans of profitability.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nDifficult; it requires successful past financing and current operational efficiency. The March 2025 underwritten public offering priced \u003cstrong\u003e25,000,000\u003c\/strong\u003e shares at \u003cstrong\u003e$2.00\u003c\/strong\u003e per share, aiming to raise \u003cstrong\u003e$50.0 million\u003c\/strong\u003e before expenses. Cash and cash equivalents were \u003cstrong\u003e$113.4 million\u003c\/strong\u003e as of March 31, 2025, including \u003cstrong\u003e$46.5 million\u003c\/strong\u003e from that offering.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh; management is using the cash to fund operations and pipeline advancement.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nVafseo net product revenues reached \u003cstrong\u003e$14.3 million\u003c\/strong\u003e in Q3 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nAuryxia net product revenues were \u003cstrong\u003e$42.5 million\u003c\/strong\u003e in Q3 2025, despite loss of exclusivity on March 20, 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nManagement is advancing pipeline, with expected prescribing access reaching approximately \u003cstrong\u003e275,000\u003c\/strong\u003e patients by year-end 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nSelling, General \u0026amp; Administrative Expenses were \u003cstrong\u003e$29.1 million\u003c\/strong\u003e in Q3 2025, up from \u003cstrong\u003e$26.5 million\u003c\/strong\u003e in Q3 2024, reflecting Vafseo launch marketing costs.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary; cash reserves deplete, and sustained advantage requires ongoing profitability. The company achieved a net income of \u003cstrong\u003e$540,000\u003c\/strong\u003e in Q3 2025, a shift from a net loss of \u003cstrong\u003e$20.0 million\u003c\/strong\u003e in Q3 2024.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Established U.S. Inventory and Supply Chain for Vafseo\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Mitigates immediate supply risk for the newly launched product, with at least \u003cstrong\u003e12 months\u003c\/strong\u003e of inventory on hand in the U.S. as of early \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; securing a long runway for a new drug launch is a significant operational feat.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires established contracts and logistics, though Akebia lacks internal manufacturing facilities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the inventory management supported the Q3 \u003cstrong\u003e2025\u003c\/strong\u003e revenue of \u003cstrong\u003e$14.3 million\u003c\/strong\u003e from Vafseo.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this buffer will eventually be consumed and must be continuously replenished.\u003c\/p\u003e\n\u003cp\u003eKey operational and financial metrics supporting the supply chain assessment:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVafseo Q3 2025 Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated U.S. Inventory Runway\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAt least 12 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of end of March 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Q3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Prescribing Access\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e275,000+ patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBy end of Q4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$166.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupply chain and access development milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVafseo U.S. commercial shipments commenced in \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCMS granted Transitional Drug Add-On Payment Adjustment (TDAPA) reimbursement effective \u003cstrong\u003eJanuary 1, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eContracts in place with dialysis organizations covering nearly all U.S. dialysis patients as of \u003cstrong\u003eJanuary 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrescribing access grew from \u003cstrong\u003e40,000 patients\u003c\/strong\u003e in early \u003cstrong\u003e2025\u003c\/strong\u003e to \u003cstrong\u003e60,000 patients\u003c\/strong\u003e by the end of \u003cstrong\u003eQ3 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe VOICE trial, conducted by USRC, enrolled \u003cstrong\u003e2,116 patients\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAkebia Therapeutics, Inc. (AKBA) - VRIO Analysis: Specialized Focus and Brand Recognition in the Renal Community\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialized Focus and Brand Recognition in the Renal Community\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Fosters trust and drives adoption, as evidenced by the high rate of prescription writing among USRC physicians (over 85% in Q3 2025).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; deep focus in a niche like kidney disease creates specialized credibility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; this reputation is built over years since the company's founding in \u003cstrong\u003e2007\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the entire company purpose is to better the lives of people impacted by kidney disease.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; deep community trust is slow to build and slow to erode.\u003c\/p\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eQ3 2025 Key Operational and Financial Metrics\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany Founding Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2007\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSRC Physicians with Prescription (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Prescribers (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e725\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Prescriptions per Prescriber (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e12.7\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRefill Prescriptions Percentage (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenues (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$58.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of Q3 2025, implied)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$166.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eVafseo (vadadustat) Prescription Dynamics (Q3 2025)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVafseo net product revenue in Q3 2025 totaled \u003cstrong\u003e$14.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAverage dose of refills increased by \u003cstrong\u003e5%\u003c\/strong\u003e versus the prior quarter.\u003c\/li\u003e\n\u003cli\u003eAverage dose of refills increased by \u003cstrong\u003e32%\u003c\/strong\u003e above the starting dose.\u003c\/li\u003e\n\u003cli\u003eTotal number of prescribers in Q3 was approximately \u003cstrong\u003e725\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eQ3 2025 Revenue Breakdown\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Revenues: \u003cstrong\u003e$58.8 million\u003c\/strong\u003e, up from \u003cstrong\u003e$37.4 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eAuryxia net product revenues: \u003cstrong\u003e$42.5 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eLicense, collaboration and other revenues: \u003cstrong\u003e$2.0 million\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516111511701,"sku":"akba-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/akba-vrio-analysis.png?v=1740143258","url":"https:\/\/dcf-model.com\/products\/akba-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}